2023 World Conference on Lung Cancer (Posters)-EP11.03. Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China

EP11.03. Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China - PDF(Abstract)

Back to course

Pdf Summary

A retrospective study was conducted in China to evaluate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, combined with chemotherapy in patients with advanced lung cancer harboring KRAS mutations. The study included 10 male patients with a median age of 55 years. Most of the patients had non-squamous cell lung cancer. Types of KRAS mutations included G12C, G12V, G12A, Q61H, and others. The objective response rate (ORR) was 66.7% and the disease control rate (DCR) was 77.8%. Median time to treatment failure (TTF) was 10.5 months and median overall survival (OS) was 12.5 months. Adverse events were observed in 80% of the patients, with most being grade 1 or 2. The most common adverse events included leukopenia, rash, and fatigue. The study concluded that tislelizumab combined with nab-paclitaxel and platinum-based chemotherapy showed promising anti-tumor efficacy and a manageable safety profile for advanced lung cancer with KRAS mutations in China. This study highlights the potential of tislelizumab as a treatment option for this patient population.

Asset Subtitle

Fengnan Wang

Meta Tag

Speaker Fengnan Wang

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

retrospective study

efficacy

safety

tislelizumab

chemotherapy

advanced lung cancer

KRAS mutations

adverse events

overall survival

treatment option